Jingsong Zhang, MD
Medical Oncology · Tampa, FLNPI 1124227780
Payments from drug & device makers
Across 1,269 payments — averaging $6248.66 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Regeneron$2.6M
- Exelixis Inc.$1.2M
- Bayer$1.2M
- Astrazeneca UK Limited$702K
- AstraZeneca$614K
- Bioxcel Therapeutics, Inc.$285K
- plus $1.3M from 29 others
Across 10 payments — averaging $305.22 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- Regeneron$2K
- Astellas Pharma Global Development$853
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Regeneron | 275 | $2,633,858 |
| Exelixis Inc. | 241 | $1,236,647 |
| Bayer | 269 | $1,157,492 |
| Astrazeneca UK Limited | 9 | $702,397 |
| AstraZeneca | 43 | $614,082 |
| Bioxcel Therapeutics, Inc. | 29 | $285,040 |
| Astellas Pharma Global Development | 13 | $258,512 |
| Clovis Oncology, Inc. | 78 | $230,411 |
| Seagen Inc. | 116 | $181,625 |
| E.r. Squibb & Sons, L.L.C. | 10 | $106,974 |
| Taiho Oncology, Inc. | 29 | $106,474 |
| Pfizer | 35 | $100,681 |
| Genentech, Inc. | 1 | $76,731 |
| Karyopharm Therapeutics Inc. | 10 | $66,256 |
| Dendreon Pharmaceuticals LLC | 18 | $59,112 |
| Sanofi | 42 | $57,077 |
| Blue Earth Diagnostics | 6 | $24,702 |
| Johnson & Johnson | 14 | $11,234 |
| Merck | 6 | $7,913 |
| Avyxa Pharma, LLC | 6 | $3,400 |
| Astellas Pharma US Inc | 4 | $2,790 |
| EMD Serono, Inc. | 1 | $2,760 |
| Tolmar, Inc. | 1 | $2,250 |
| Eisai Inc. | 2 | $214 |
| AVEO Pharmaceuticals, Inc. | 1 | $151 |
| Secura Bio, Inc. | 1 | $125 |
| Novartis | 1 | $124 |
| Pharmaessentia USA Corporation | 1 | $122 |
| Beigene USA, Inc. | 1 | $115 |
| Spark Therapeutics, Inc. | 1 | $95 |
| Amgen | 1 | $88 |
| Genentech USA, Inc. | 1 | $36 |
| AbbVie | 1 | $26 |
| Array Biopharma Inc | 1 | $25 |
| Sanofi-aventis U.S. LLC | 1 | $9 |
How this compares
$7,929,549 in reported general payments places this provider in the 95th percentile of 507 medical oncology providers in Florida.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Other medical oncology in Tampa
- Zeynep ErogluTampa$30.9M
- Jad ChahoudTampa$21.8M
- Patrick HwuTampa$18M
- Adil DaudTampa$13.3M
- Jonathan StrosbergTampa$9.7M
- Sameh GaballaTampa$7.8M
- Alberto ChiapporiTampa$7.4M
- Christine ChungTampa$6.6M
- Mihaela DrutaTampa$5.6M
- Hyo HanTampa$5.2M
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.